{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:49:58Z","timestamp":1768337398815,"version":"3.49.0"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1009715","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000}}],"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Bispecific T cell engagers (TCEs) are an emerging anti-cancer modality that redirects cytotoxic T cells to tumor cells expressing tumor-associated antigens (TAAs), thereby forming immune synapses to exert anti-tumor effects. Designing pharmacokinetically acceptable TCEs and optimizing their size presents a considerable protein engineering challenge, particularly given the complexity of intercellular bridging between T cells and tumor cells. Therefore, a physiologically-relevant and clinically-verified computational modeling framework is of crucial importance to understand the protein engineering trade-offs. In this study, we developed a quantitative, physiologically-based computational framework to predict immune synapse formation for a variety of molecular formats of TCEs in tumor tissues. Our model incorporates a molecular size-dependent biodistribution using the two-pore theory, extravasation of T cells and hematologic cancer cells, mechanistic bispecific intercellular binding of TCEs, and competitive inhibitory interactions by shed targets. The biodistribution of TCEs was verified by positron emission tomography imaging of [<jats:sup>89<\/jats:sup>Zr]AMG211 (a carcinoembryonic antigen-targeting TCE) in patients. Parameter sensitivity analyses indicated that immune synapse formation was highly sensitive to TAA expression, degree of target shedding, and binding selectivity to tumor cell surface TAAs over shed targets. Notably, the model suggested a \u201csweet spot\u201d for TCEs\u2019 CD3 binding affinity, which balanced the trapping of TCEs in T-cell-rich organs. The final model simulations indicated that the number of immune synapses is similar (~55\/tumor cell) between two distinct clinical stage B cell maturation antigen (BCMA)-targeting TCEs, PF-06863135 in an IgG format and AMG420 in a BiTE format, at their respective efficacious doses in multiple myeloma patients. This result demonstrates the applicability of the developed computational modeling framework to molecular design optimization and clinical benchmarking for TCEs, thus suggesting that this framework can be applied to other targets to provide a quantitative means to facilitate model-informed best-in-class TCE discovery and development.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1009715","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T17:36:43Z","timestamp":1657906603000},"page":"e1009715","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2207-3505","authenticated-orcid":true,"given":"Tomoki","family":"Yoneyama","sequence":"first","affiliation":[]},{"given":"Mi-Sook","family":"Kim","sequence":"additional","affiliation":[]},{"given":"Konstantin","family":"Piatkov","sequence":"additional","affiliation":[]},{"given":"Haiqing","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Andy Z. X.","family":"Zhu","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"issue":"8","key":"pcbi.1009715.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0130-1","article-title":"Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance","volume":"50","author":"YJ Park","year":"2018","journal-title":"Exp Mol Med"},{"issue":"1","key":"pcbi.1009715.ref002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"JA Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"6382","key":"pcbi.1009715.ref003","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"CH June","year":"2018","journal-title":"Science"},{"issue":"6","key":"pcbi.1009715.ref004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic Viruses in Cancer Treatment: A Review.","volume":"3","author":"SE Lawler","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"pcbi.1009715.ref005","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond.","volume":"17","author":"ME Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"pcbi.1009715.ref006","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.","volume":"11","author":"C Caraccio","year":"2020","journal-title":"Front Immunol."},{"key":"pcbi.1009715.ref007","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"FV Suurs","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"4","key":"pcbi.1009715.ref008","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00432-019-02867-6","article-title":"T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances","volume":"145","author":"L Yu","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"pcbi.1009715.ref009","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: design, therapy, perspectives.","volume":"12","author":"SE Sedykh","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"pcbi.1009715.ref010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12459","article-title":"Clinical Pharmacology and Translational Aspects of Bispecific Antibodies.","volume":"10","author":"A Trivedi","year":"2017","journal-title":"Clin Transl Sci"},{"issue":"3","key":"pcbi.1009715.ref011","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/cpt.393","article-title":"Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK\/PD Modeling Approach","volume":"100","author":"X Chen","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"pcbi.1009715.ref012","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/19420862.2018.1480299","article-title":"Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents.","volume":"10","author":"X Jiang","year":"2018","journal-title":"MAbs"},{"issue":"11","key":"pcbi.1009715.ref013","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1158\/1078-0432.CCR-17-2265","article-title":"Integrated Pharmacokinetic\/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity","volume":"24","author":"O Campagne","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"pcbi.1009715.ref014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12248-019-0332-z","article-title":"A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART((R)).","volume":"21","author":"A Betts","year":"2019","journal-title":"AAPS J."},{"issue":"1","key":"pcbi.1009715.ref015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/acsptsci.0c00178","article-title":"Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development.","volume":"4","author":"H Ma","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"pcbi.1009715.ref016","doi-asserted-by":"crossref","first-page":"105260","DOI":"10.1016\/j.ejps.2020.105260","article-title":"Development of a minimal physiologically-based pharmacokinetic\/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans","volume":"146","author":"X Jiang","year":"2020","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"pcbi.1009715.ref017","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling","volume":"6","author":"I Hosseini","year":"2020","journal-title":"NPJ Syst Biol Appl"},{"issue":"4","key":"pcbi.1009715.ref018","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1208\/s12248-020-00450-3","article-title":"A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor.","volume":"22","author":"H Ma","year":"2020","journal-title":"AAPS J"},{"issue":"10","key":"pcbi.1009715.ref019","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a Bispecific T-cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.","volume":"55","author":"M Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"pcbi.1009715.ref020","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/dmd.119.087809","article-title":"Effect of Size on Solid Tumor Disposition of Protein Therapeutics","volume":"47","author":"Z Li","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"pcbi.1009715.ref021","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1007\/s10439-005-7410-3","article-title":"A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).","volume":"33","author":"GZ Ferl","year":"2005","journal-title":"Ann Biomed Eng"},{"issue":"5","key":"pcbi.1009715.ref022","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10928-007-9065-1","article-title":"Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.","volume":"34","author":"A Garg","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"pcbi.1009715.ref023","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.","volume":"39","author":"DK Shah","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"pcbi.1009715.ref024","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10928-019-09639-2","article-title":"Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.","volume":"46","author":"Z Li","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"pcbi.1009715.ref025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10928-014-9402-0","article-title":"Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory","volume":"42","author":"A Sepp","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"pcbi.1009715.ref026","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1208\/s12248-015-9819-4","article-title":"A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins.","volume":"18","author":"KL Gill","year":"2016","journal-title":"AAPS J"},{"issue":"1","key":"pcbi.1009715.ref027","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1152\/physrev.1994.74.1.163","article-title":"Transport of macromolecules across microvascular walls: the two-pore theory","volume":"74","author":"B Rippe","year":"1994","journal-title":"Physiol Rev"},{"issue":"12","key":"pcbi.1009715.ref028","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1158\/1078-0432.CCR-18-2918","article-title":"(89)Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake.","volume":"25","author":"KL Moek","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"pcbi.1009715.ref029","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","article-title":"Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma","volume":"18","author":"SH Panowski","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"pcbi.1009715.ref030","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"S Hipp","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"pcbi.1009715.ref031","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1208\/s12248-016-0004-1","article-title":"Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling.","volume":"19","author":"A Tiwari","year":"2017","journal-title":"AAPS J."},{"issue":"23","key":"pcbi.1009715.ref032","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood.V126.23.2999.2999","article-title":"BI 836909, a Novel Bispecific T Cell Engager for the Treatment of Multiple Myeloma Induces Highly Specific and Efficacious Lysis of Multiple Myeloma Cells in Vitro and Shows Anti-Tumor Activity in Vivo","volume":"126","author":"S Hipp","year":"2015","journal-title":"Blood"},{"issue":"10","key":"pcbi.1009715.ref033","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.exphem.2007.06.016","article-title":"Characterization of in vitro growth of multiple myeloma cells","volume":"35","author":"M Zlei","year":"2007","journal-title":"Exp Hematol"},{"issue":"3","key":"pcbi.1009715.ref034","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1124\/jpet.118.252858","article-title":"Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice","volume":"368","author":"A Khot","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"pcbi.1009715.ref035","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s11095-017-2219-y","article-title":"Influence of Molecular size on the clearance of antibody fragments","volume":"34","author":"Z Li","year":"2017","journal-title":"Pharm Res"},{"issue":"4","key":"pcbi.1009715.ref036","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models.","volume":"13","author":"RP Brown","year":"1997","journal-title":"Toxicol Ind Health"},{"key":"pcbi.1009715.ref037","volume-title":"Wintrobe\u2019s Clinical Hematology","author":"JP Greer","year":"2018","edition":"14"},{"issue":"7","key":"pcbi.1009715.ref038","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/BF00184787","article-title":"Distribution of lymphocyte subsets and natural killer cells in the human body.","volume":"70","author":"J Westermann","year":"1992","journal-title":"Clin Investig."},{"issue":"1","key":"pcbi.1009715.ref039","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1365-2141.1997.72653.x","article-title":"Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage","volume":"97","author":"AC Rawstron","year":"1997","journal-title":"Br J Haematol"},{"issue":"5","key":"pcbi.1009715.ref040","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells","volume":"29","author":"KM Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"3","key":"pcbi.1009715.ref041","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2567.2003.01742.x","article-title":"Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vbeta repertoire","volume":"110","author":"A Battaglia","year":"2003","journal-title":"Immunology"},{"issue":"1","key":"pcbi.1009715.ref042","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cmi.2011.47","article-title":"Bone marrow and the control of immunity","volume":"9","author":"E Zhao","year":"2012","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"pcbi.1009715.ref043","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1309\/AJCPPIBH3I1VRWXQ","article-title":"Splenic lymphoid subsets with less well-recognized phenotypes mimic aberrant antigen expression","volume":"140","author":"N Aggarwal","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"pcbi.1009715.ref044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mbs.2017.07.006","article-title":"An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol","volume":"292","author":"M Qomlaqi","year":"2017","journal-title":"Math Biosci"},{"issue":"4","key":"pcbi.1009715.ref045","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"M Ghermezi","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"pcbi.1009715.ref046","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","volume":"31","author":"A Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"8","key":"pcbi.1009715.ref047","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.","volume":"38","author":"MS Topp","year":"2020","journal-title":"J Clin Oncol."},{"key":"pcbi.1009715.ref048","volume-title":"Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma.","author":"S Danehy","year":"2020"},{"issue":"4","key":"pcbi.1009715.ref049","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/1535-7163.MCT-17-0657","article-title":"Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model","volume":"17","author":"D Mandikian","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"pcbi.1009715.ref050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety.","volume":"154","author":"D. Ellerman","year":"2019","journal-title":"Methods"},{"issue":"8","key":"pcbi.1009715.ref051","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.molimm.2006.09.032","article-title":"CD19-\/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis","volume":"44","author":"M Molhoj","year":"2007","journal-title":"Mol Immunol"},{"issue":"5","key":"pcbi.1009715.ref052","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.nucmedbio.2010.12.011","article-title":"In vivo biodistribution and accumulation of 89Zr in mice.","volume":"38","author":"DS Abou","year":"2011","journal-title":"Nucl Med Biol."},{"key":"pcbi.1009715.ref053","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Levy MY, P. DA, Bahlis N, Solh M, Sebag M, et al. Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM). 62nd ASH Annual Meeting and Exposition. 2020.","DOI":"10.1182\/blood-2020-133355"},{"issue":"3","key":"pcbi.1009715.ref054","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jcph.4","article-title":"The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model","volume":"53","author":"L Zhao","year":"2013","journal-title":"J Clin Pharmacol"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1009715","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1009715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T18:27:25Z","timestamp":1676140045000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1009715"}},"subtitle":[],"editor":[{"given":"Rotem","family":"Rubinstein","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1009715","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1009715","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]}}}